Alpha 2.0

» Articles » PMID: 37760983

Evaluating the Causal Association Between Inflammatory Bowel Disease and Risk of Atherosclerotic Cardiovascular Disease: Univariable and Multivariable Mendelian Randomization Study

Overview

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Sep 28

PMID 37760983

Authors

Authors

Baike Liu

Zijian Qin

Zhaolun Cai

Zheran Liu

Yun-Lin Chen

Xiaonan Yin

Yuan Yin

Xingchen Peng

Bo Zhang

Affiliations

Affiliations

Soon will be listed here.

Abstract

Background: Observational studies suggested that inflammatory bowel disease (IBD) (i.e., Crohn's disease [CD] and ulcerative colitis [UC]) is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease (CAD) and ischemic stroke. However, it is still unclear whether the observed associations causally exist. Thus, we aim to examine the potential effect of IBD, CD, and UC on the risk of CAD and ischemic stroke, using a two-sample Mendelian randomization (MR) study.

Methods: Genetic instruments for IBD, CD, and UC were retrieved from the latest published genome-wide association studies (GWASs) of European ancestry. GWAS summary data for instrument-outcome associations were gathered from four independent resources: CARDIoGRAMplusC4D Consortium, MEGASTROKE consortium, FinnGen, and UK Biobank. The inverse variance weighted (IVW) method and multiple pleiotropy-robust approaches were conducted and, subsequently, combined in a fixed-effect meta-analysis. Moreover, multivariable MR (MVMR) analysis was conducted to adjust for potential influencing instrumental variables.

Results: The IVW method revealed no causal effect of IBD on the risk of CAD (overall IBD on CAD: OR 1.003, 95%CI 0.982 to 1.025; CD on CAD: OR 0.997, 95%CI 0.978 to 1.016; UC on CAD: OR 0.986, 95%CI 0.963 to 1.010) or the risk of ischemic stroke (overall IBD on ischemic stroke: OR 0.994, 95%CI 0.970 to 1.018; CD on ischemic stroke: OR 0.996, 95%CI 0.979 to 1.014; UC on ischemic stroke: OR 0.999, 95%CI 0.978 to 1.020). The results of the meta-analysis and MVMR remained consistent.

Conclusion: Our MR analysis does not support a causal effect of IBD on CAD and ischemic stroke, and previous results from observational studies might be biased through uncontrolled confoundings (such as IBD-specific medications and detection bias, etc.) that warrant further research.

Citing Articles

Immune-Mediated Bidirectional Causality Between Inflammatory Bowel Disease and Chronic Periodontitis: Evidence from Mendelian Randomization and Integrative Bioinformatics Analysis.

Feng Z, Chen Z, Wang X, Zhou M, Liu S Biomedicines. 2025; 13(2).

PMID: 40002889 PMC: 11853167. DOI: 10.3390/biomedicines13020476.

Autoimmune diseases and cardiovascular risk: Mendelian randomization analysis for the impact of 19 autoimmune diseases on 14 cardiovascular conditions.

Bao Y, Gu L, Chen J, Wang H, Wang Z, Wang H J Transl Autoimmun. 2024; 9:100259.

PMID: 39554254 PMC: 11565429. DOI: 10.1016/j.jtauto.2024.100259.

Mendelian randomization analysis of psoriasis and psoriatic arthritis associated with risks of ulcerative colitis.

Pan J, Lv Y, Wang L, Chang X, Zhao K, Liu X Skin Res Technol. 2024; 30(7):e13795.

PMID: 38995229 PMC: 11242227. DOI: 10.1111/srt.13795.

References

1.

Ji S, Juran B, Mucha S, Folseraas T, Jostins L, Melum E . Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2016; 49(2):269-273. PMC: 5540332. DOI: 10.1038/ng.3745. View

2.

Sun J, Halfvarson J, Appelros P, Bergman D, Ebrahimi F, Roelstraete B . Long-term Risk of Stroke in Patients With Inflammatory Bowel Disease: A Population-Based, Sibling-Controlled Cohort Study, 1969-2019. Neurology. 2023; 101(6):e653-e664. PMC: 10424828. DOI: 10.1212/WNL.0000000000207480. View

3.

Singh S, Singh H, Loftus Jr E, Pardi D . Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013; 12(3):382-93.e1: quiz e22. DOI: 10.1016/j.cgh.2013.08.023. View

4.

Fausa O, Schrumpf E, Elgjo K . Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis. 1991; 11(1):31-9. DOI: 10.1055/s-2008-1040420. View

5.

Huang W, Tseng C, Chen P, Tsai C, Lin C, Sung F . Inflammatory bowel diseases increase future ischemic stroke risk: a Taiwanese population-based retrospective cohort study. Eur J Intern Med. 2014; 25(6):561-5. DOI: 10.1016/j.ejim.2014.05.009. View

6.

Bili A, Tang X, Pranesh S, Bozaite R, Morris S, Antohe J . Tumor necrosis factor α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013; 66(3):355-63. DOI: 10.1002/acr.22166. View

7.

Davey Smith G, Hemani G . Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014; 23(R1):R89-98. PMC: 4170722. DOI: 10.1093/hmg/ddu328. View

8.

Sanderson E, Spiller W, Bowden J . Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization. Stat Med. 2021; 40(25):5434-5452. PMC: 9479726. DOI: 10.1002/sim.9133. View

9.

Feng W, Chen G, Cai D, Zhao S, Cheng J, Shen H . Inflammatory Bowel Disease and Risk of Ischemic Heart Disease: An Updated Meta-Analysis of Cohort Studies. J Am Heart Assoc. 2017; 6(8). PMC: 5586435. DOI: 10.1161/JAHA.117.005892. View

10.

Burgess S, Davey Smith G, Davies N, Dudbridge F, Gill D, Glymour M . Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res. 2023; 4:186. PMC: 7384151. DOI: 10.12688/wellcomeopenres.15555.3. View

11.

Adams Jr H, Bendixen B, Kappelle L, Biller J, Love B, Gordon D . Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24(1):35-41. DOI: 10.1161/01.str.24.1.35. View

12.

Bigeh A, Sanchez A, Maestas C, Gulati M . Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease?. Trends Cardiovasc Med. 2019; 30(8):463-469. DOI: 10.1016/j.tcm.2019.10.001. View

13.

Virani S, Alonso A, Aparicio H, Benjamin E, Bittencourt M, Callaway C . Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021; 143(8):e254-e743. DOI: 10.1161/CIR.0000000000000950. View

14.

Zhao D, Liu J, Wang M, Zhang X, Zhou M . Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2018; 16(4):203-212. DOI: 10.1038/s41569-018-0119-4. View

15.

Ridker P . Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. Circ Res. 2019; 124(3):437-450. PMC: 6386195. DOI: 10.1161/CIRCRESAHA.118.313129. View

16.

Karlsen T, Folseraas T, Thorburn D, Vesterhus M . Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017; 67(6):1298-1323. DOI: 10.1016/j.jhep.2017.07.022. View

17.

Bowden J, Davey Smith G, Haycock P, Burgess S . Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016; 40(4):304-14. PMC: 4849733. DOI: 10.1002/gepi.21965. View

18.

Peyrin-Biroulet L, Reinisch W, Colombel J, Mantzaris G, Kornbluth A, Diamond R . Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2013; 63(1):88-95. DOI: 10.1136/gutjnl-2013-304984. View

19.

Thapa S, Hadid H, Schairer J, Imam W, Jafri S . Effect of Inflammatory Bowel Disease-Related Characteristics and Treatment Interventions on Cardiovascular Disease Incidence. Am J Med Sci. 2015; 350(3):175-80. DOI: 10.1097/MAJ.0000000000000535. View

20.

Ridker P, Libby P, MacFadyen J, Thuren T, Ballantyne C, Fonseca F . Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018; 39(38):3499-3507. DOI: 10.1093/eurheartj/ehy310. View